Companies are working hard to create the medicines of the future for people with rare diseases. In order to get those medicines to patients, they are evaluated by a number of regulators to make sure they are safe, effective and value for money for the NHS.
When working on a medicine for a rare disease, companies are inevitably working with smaller numbers of patients and therefore uncertainty in the evidence, which means that getting a medicine for a rare disease approved can pose a challenge. When there is a medicine available for a rare disease, we want to make sure that people who need it can get it quickly.
The NICE Methods and Process Review
The National Institute of Health and Care Excellence (NICE) is the body which advises the NHS on whether a new medicine is cost effective.
NICE is currently reviewing its methods and processes and is looking at how to address uncertainty in the evidence for a medicine.
The way that NICE calculates value for money for the NHS hasn’t changed in more than 20 years. These calculations need to be more flexible to reflect the full impact of new medicines on patients, carers, the NHS and society.
- We are working with NICE on their review to overcome some of the challenges of uncertain evidence. One way this could happen is for NICE to use ‘conditional approvals’ for a medicine so that more data can be collected to resolve some uncertainty and patients can access new medicines as soon as possible.
- NICE should look at the value of medicines in a much broader way. For example, more account needs to be taken of disease severity, rarity and the impact a new medicine has on the patient and their family/carers.
- It is essential that the UK continues to collaborate internationally to safeguard valuable research on rare diseases, particularly now we have left the EU.
- We are arguing strongly to maintain a future relationship with the EU that means we can continue to participate in European Reference Networks.
Evolving the UK health system to support innovation for the Rare Disease community
Nicola Redfern, General Manager of Bluebird Bio in the UK, describes the commercial challenges for rare disease medicines in the UK and reflects on the opportunities of gene therapies.Read Nicola outlining the commercial challenges
Rare clinical research: Maximising the chances of success
Our President Haseeb Ahmad sets out how our industry is working to find treatments and cures for some of the world’s most complex diseases. Nowhere is the need to find new medicines more acute than in rare diseases, many of which are genetic and affect the youngest patients.Haseeb sets out what our industry is doing
Lets make rare disease treatments less rare
Genome sequencing and advanced therapies give hope to people with rare diseases and their families – our President Haseeb Ahmad says we have to get them into the hands of patients.Haseeb explains how we will make rare disease treatments less rare